FIELD: medicine.
SUBSTANCE: claimed are versions of polypeptides with Fc-segment from IgG, which possess increased binding FcRn due to introduction of mutation 308C, 308F, 308W, 308Y or modified binding with introduction of mutation 252Y/308F, 257L/308F, 257L/308Y, 257N/308Y, 279Q/308F, 279Y/308F, ^281S/308F, ^A281S/308Y, 284E/308F, 298A/308F/333A/334A, 308F/332E, 308F/311V, 308F/G385H, 308F/428L, and 308F/434Y. Described is antibody with said mutations in Fc region, as well as application of said Fc regions for obtaining fused protein. Application of the invention provides novel Fc-versions with modified FcRn binding.
EFFECT: possibility of application in medicine for obtaining various constructions, with prolonged time of preservation in blood serum in vivo or, vice versa, in case of therapy with application of radioactive medications, with reduced time of preservation in blood serum in vivo.
14 cl, 44 dwg, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| Fc-VERSIONS WITH ALTERED BINDING WITH FcRn | 2008 |
|
RU2517621C2 |
| Fc VERSIONS WITH MODIFIED BINDING WITH FcRn | 2008 |
|
RU2529951C2 |
| VARIANTS OF Fc WITH CHANGED BINDING WITH FcRn | 2014 |
|
RU2700882C2 |
| OPTIMIZED Fc-VERSIONS THAT HAVE ALTERED BINDING TO FcγR AND METHODS FOR THEIR PRODUCTION | 2004 |
|
RU2337107C2 |
| ANTIBODY Fc VARIANTS | 2012 |
|
RU2607014C2 |
| CHEMERIC IMPROVED RECOMBINANT FACTOR VIII | 2015 |
|
RU2647769C2 |
| AFFINITY CHROMATOGRAPHY WITH APPLICATION OF Fc-RECEPTORS | 2013 |
|
RU2624128C2 |
| INTRATHECAL ADMINISTRATION OF VECTORS BASED ON ADENO ASSOCIATED VIRUSES FOR GENE THERAPY | 2016 |
|
RU2775138C2 |
| Fc-RECEPTOR BINDING MODIFIED ASYMMETRIC ANTIBODIES AND METHODS OF USE | 2014 |
|
RU2687043C2 |
| VERSIONS OF ALBUMIN | 2012 |
|
RU2650784C2 |
